AUTHORS
Elaine Xie, MBA, Joseph Rocco, MD2, Gaurav Goyal, MD3, Matthew Wojdyla, PharmD4, Kim-Hien Dao, DO, PhD5, Kathy Dong, PharmD, MBA6, Pamela Allen, MD7
AFFILIATIONS
1 Electra Therapeutics, Inc., South San Francisco, California, United States
2 National Institutes of Health, Bethesda, Maryland, United States
3 University of Alabama at Birmingham, Birmingham, Alabama, United States
4 Electra Therapeutics, Inc., South San Francisco, California, United States
5 Electra Therapeutics, Inc., South San Francisco, California, United States
6 Electra Therapeutics, Inc., South San Francisco, California, United States
7 Emory University School of Medicine, Atlanta, Georgia, United States
ABSTRACT
Background
Secondary hemophagocytic lymphohistiocytosis (sHLH) is a life-threatening hyperinflammatory syndrome triggered by malignancy, infection, autoimmune disease, or immune-activating therapies. Despite increasing recognition of sHLH in adults, contemporary population-level estimates remain limited because existing studies often rely on hospitalization-level data, single-country registries, or nonadjudicated administrative codes. We performed a national claims-based analysis to estimate the annual burden of claims-defined sHLH in the US and to describe associated clinical contexts, treatment patterns, and sites of care.
Methods
We conducted a retrospective analysis of deidentified US claims from the Komodo Health database from January 1, 2016, through December 31, 2025. Patients with claims containing ICD-10-CM codes D76.1, D76.2, or D76.3 or ICD-9-CM code 288.4 were identified. Patients with multiple qualifying codes in the same calendar year were assigned hierarchically to D76.1, D76.2, 288.4, and D76.3. Patients with likely primary HLH, defined algorithmically as age <2 years or undergoing hematopoietic stem cell transplantation before age 10 years, were excluded. Patients identified solely by D76.3 were retained only if they had an HLH-compatible clinical feature within 30 days and an HLH-compatible treatment within 90 days of the index claim.
The primary outcome was annual first-observed, claims-defined sHLH, defined as the first calendar year in which a patient met the study algorithm. Recurrent episodes were defined as subsequent qualifying claims occurring >1 year after a prior qualifying sHLH claim. National estimates were generated using age-band adjustment and annual scaling factors. Associated clinical contexts, including malignancy, viral infection, autoimmune disease, and immune-activating therapies, were identified using diagnosis and treatment claims in prespecified windows around the index sHLH claim. Treatment patterns were assessed using medication claims within 90 days after the index claim.
Results
In 2025, 15,911 patients had ≥1 qualifying HLH or HLH-adjacent diagnosis code. After excluding likely primary HLH, applying the D76.3 enrichment algorithm, and removing patients with qualifying claims in prior years, 4066 patients met criteria for first-observed, claims-defined sHLH. Extrapolation to the US population yielded an estimated 12,621 claims-defined sHLH episodes, comprising 10,143 first-observed cases plus recurrent episodes occurring >1 year after a prior qualifying claim. Approximately 64% of patients received care at academic medical centers. Estimated total sHLH cases increased from 5609 in 2016 to 12,621 in 2025, representing a compound annual growth rate (CAGR) of 9.4%. Growth accelerated from 2021 to 2025, with a CAGR of 11.5%.
Among patients with claims-defined sHLH episodes in 2025, malignancy was the most common associated clinical context, present in 42%, including hematologic malignancy in 33% and solid malignancy in 9%. Viral infection was identified in 34%, autoimmune disease in 27%, and immune-activating therapies in 3%. Categories were not mutually exclusive. Immune-activating therapies showed the greatest growth over the 2016-2025 study period (CAGR, 70%). Corticosteroids were the most observed treatment. Other therapies included cyclosporine, methotrexate, etoposide, anakinra, ruxolitinib, intravenous immunoglobulin, antiviral agents, and malignancy-directed therapies.
Conclusions
In this national claims-based analysis, the population-adjusted burden of claims-defined sHLH in the US increased significantly from 2016 to 2025 (P<.05), reaching an estimated 12,621 sHLH episodes. Growth likely reflects improved recognition and coding, increasing immune-activating therapy-associated sHLH, and the rising prevalence of some hematologic malignancies. Malignancy was the most common associated clinical context. Treatment was heterogeneous and dominated by corticosteroids, consistent with variable real-world practice and the lack of a broadly accepted standard of care. Most patients were treated at academic centers, although care was also distributed across nonacademic settings. These findings demonstrate a substantial and growing burden of sHLH in the US and underscore the urgent need for more effective and standardized approaches to diagnosis and treatment.
DISCLOSURES
Elaine Xie, MBA: Electra Therapeutics, Inc - Current holder of stock options in a privately-held company; Electra Therapeutics, Inc - Current Employment